NCT00093015 - Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT) | Biotech Hunter

Enrollment

4,038

Participants

Timeline

Start Date

August 1, 2004

Primary Completion Date

March 1, 2009

Study Completion Date

July 1, 2009

Conditions

Kidney DiseaseDiabetes MellitusAnemia

Interventions

DRUG

Placebo

Volume and dose frequency changes resembling dosing in the active treatment group

DRUG

darbepoetin alfa

Starting dose : 0.75 mcg/kg subcutaneous (SC) every two weeks (Q2W); subsequent doses titrated to achieve hemoglobin (Hb) target of 13.0 g/dL